<?xml version="1.0" encoding="UTF-8"?>
<p id="Par119">Two other randomized trials, SARON and CORE investigate the same approach in different clinical settings with oligometastatic patients [
 <xref ref-type="bibr" rid="CR36">36</xref>]s. With respect to these two studies, Stereo-OS will allow a specific focus on skeletal metastases only and is thus expected to bring a clear-cut assessment of the added benefit of stereotactic radiotherapy on PFS in the especially dedicated treatment of a highly frequently occurring type of metastases in solid tumor cancers.
</p>
